Sarcomas are a diverse and relatively rare group of malignant tumors that develop in soft tissue and bone. Soft tissue and bone sarcoma incidence rates, according to the National Cancer Institute, have increased over the past 35 years, with soft tissue sarcomas more common.
Duke Cancer Institute’s Sarcoma disease group uses a multidisciplinary, patient-centric approach to diagnose and treat both bone and soft-tissue sarcomas. Through unsurpassed clinical care, personalized treatment planning and delivery, and state-of-the-art basic scientific and clinical research, the program is the center of excellence for the treatment of sarcoma in the Southeast and beyond.
Our strengths include:
A multidisciplinary clinic
Prospective multidisciplinary database
Monthly multidisciplinary research conferences
Weekly multidisciplinary clinical case conferences
Internationally recognized sarcoma research program
To make an appointment, please call 919.535.4696. For more information on sarcoma cancer care at Duke Health, visit Sarcoma. To find a doctor, visit Find A Specialist.
We have created a robust basic, translational and clinical research portfolio.
With a goal to fast-track the design and approval of clinical trials, our scientists are leading the way in the research of sarcoma and studying the cancer in children as well as adults. We aim to have a clinical trial option for every patient.
We are investigating, in the lab, possible agents to fight rhabdomyosarcoma and other sarcoma subtypes.
Our researchers have conducted and are conducting several sarcoma-specific clinical trials, including pharmaceutically-sponsored, investigator-initiated and cooperative group trials.
Duke Cancer Institute constellates the world-class resources of Duke University, Duke Health and the Duke Comprehensive Cancer Center into a collaborative powerhouse. We are poised to drive a paradigm shift in the way long-established cancer centers and institutes have been waging this war.